Program launch date: March 2020
The impact of migraine on quality of life and work-related activity is substantial but underestimated. However, migraine burden is difficult to assess both quantitatively and qualitatively due to the transient nature of migraine headaches and patient-reporting inconsistencies. The fact that headache disorders account for over 60% of neurological conditions and, according to recent analysis using disease-specific measures, reported in the Global Burden of Disease study, disability-adjusted life years (DALYs) run into the millions, suggests that there is a significant gap between knowledge and practice.
This new expert-led curriculum-based program covers the latest advances in migraine classification and acute management and will help you translate this knowledge into your clinical practice and improve your patients’ outcomes. The content has been published in phases, following a predetermined curriculum of learning activities which develop from the first stage, knowledge, moving onto competence and finally ending with performance.
The program is suitable for healthcare professionals worldwide who provide front-line care of patients with acute migraine, particularly primary care practitioners, internists and clinicians without a specialty in headache. It will also reinforce the existing knowledge of headache specialists.
Uwe Reuter discusses how to assess the efficacy of migraine treatment and when to change treatment plans.
Learners will be able to:
- Utilize the latest pathophysiological advances to improve the identification and classification of migraine
- Debate and adopt appropriately tailored acute migraine treatment to the individual patient to optimize safety, efficacy, and adherence
- Evaluate the latest data on novel acute treatments and discuss where their use may be incorporated into current clinical practice
- Interpret the success of acute migraine treatment using up-to-date clinical endpoints
Uwe Reuter, Program Director
Professor of Neurology, Charité University Hospital, Berlin, Germany
Prof Dr Uwe Reuter is a neurologist and partner in the headache program at Charité Universitätsmedizin Berlin, Germany. Upon completing his residency training in Berlin he attended Harvard Medical School as a postdoctoral fellow. During his time in Boston he focused on basic research in primary headaches and migraine aura, and published several peer-reviewed publications in high impact journals. Uwe Reuter has been the principal investigator in numerous clinical trials and projects. He has published multiple manuscripts on CGRP and is the lead author in the first placebo controlled clinical trial with a monoclonal CGRP antibody for migraine prevention in patients, who previously did not respond to 2-4 conventional oral migraine preventatives.
He is a member of several national and international headache organizations and currently serves as a board member of the European Headache Federation.
Disclosures
Uwe Reuter discloses financial support and/or sponsorship from Allergan, Amgen, Novartis, Eli Lilly, TEVA, Medscape, and StreamedUp.
Mario Peres
Professor, Psychiatry Institute, Sao Paulo University, Sao Paulo, Brazil
Mario Peres is a neurologist, who for the past 20 years has been dedicated to headache research, clinical practice, academic training and public awareness. He is currently President of ABRACES, a Brazilian headache advocacy association, Secretary of the Brazilian Headache Society, member of the Board of Trustees of the International Headache Society, and Professor at the Psychiatry Institute, University of Sao Paulo, Brazil.
Disclosures
Mario Peres discloses financial support/sponsorship from Lilly, Allergan, and Novartis in speaker fees, and consultation fees from Eurofarma, Lilly, Sanofi. Peres holds patent # BR2020170233532, from INPI – Instituto Nacional da Propriedade Industrial. Registered on 30/10/2017.
Nada Hindiyeh
Nada Hindiyeh MD is a board-certified neurologist and headache specialist and is currently a clinical assistant professor in the Department of Neurology at Stanford University. She is the Director of Clinical Research for the Stanford division of Headache Medicine and serves as principal investigator for several clinical trials.
She was awarded the 2013 Clinical Research Fellowship in Neurotoxins by the American Academy of Neurology and under this scholarship is currently investigating a diagnostic screening protocol for chronic migraine. Other research interests include pathophysiology and novel treatments for migraine, the use of transcranial magnetic stimulation in headache disorders, and participation in clinical trials for new headache therapeutics. She is currently a member of the American Headache Society (AHS), serves on the AHS Electronic Media Committee and was chosen as an AHS Emerging Leader in the field in 2017. She is also a member of the International Headache Society.
Dr. Hindiyeh completed her medical degree at the University of Toledo College of Medicine in Toledo, Ohio. Both her internship and neurology residencies were completed at the University of California Irvine Medical Center, where she was Chief Resident. She completed her fellowship in headache and facial pain at Stanford University School of Medicine.
Disclosures
Nada Hindiyeh discloses honoraria for advisory boards/consulting from Eli Lilly, Alder/Lundbeck, and Amgen/Novartis.
Shih-Pin Chen
Attending Neurologist and Professor, Department of Medical Research and Department of Neurology, Taipei Veterans General Hospital, Taipei, TAIWAN
Shih-Pin Chen is a physician scientist who graduated from Faculty of Medicine and Institute of Clinical Medicine, National Yang-Ming University, Taiwan. He received his neurology resident training at Department of Neurology, Taipei Veterans General Hospital and post-doctoral fellowship training at Neurovascular Research Lab, Massachusetts General Hospital, Harvard Medical School.
Dr Chen is currently an attending physician of Department of Medical Research, Taipei Veterans General Hospital and Professor of Institute of Clinical Medicine, National Yang-Ming University. He has served as the Associate Editor of Cephalalgia (the official journal of International Headache Society) and Cephalalgia Reports since 2020. Dr Chen’s research interests focus on deciphering the pathophysiology of headache disorders, specifically, the clinical, neuroimaging, and molecular biological studies of reversible cerebral vasoconstriction syndrome (RCVS) as well as the animal models (especially cortical spreading depression) and genomics studies of migraine.
Disclosures
Shih-Pin Chen discloses speaker honorarium from Eli Lilly & Company.
This activity is supported by an educational grant from Lilly.
Through a variety of engaging learning techniques and content, the story of migraine unfolds as learners discover more about the pathophysiology and how better patient communication and accurate diagnosis will lead to best-practice management and treatment and help translate knowledge into practice. The webcast is available in multiple languages.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
The program is certified with AMA PRA Category 1 Credits™; the amount of credits are listed below. Participants should claim only credit commensurate with the extent of their participation in the activities.
The following activities are accredited:
- Phase 3: Four case studies with 0.25 credits per activity. Expiration date: February 2022
- Phase 3: eLearning module on measuring treatment success with 0.25 credits. Expiration date: February 2022
- Phase 4: 1-hour video webcast with 1.0 credit. Expiration date: July 2022
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Planning committee
In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Greaton Sellers, Jules Morgan, and Rebecca Cox. Greaton Sellers, Jules Morgan and Rebecca Cox have no financial relationships to disclose.
Follow the instructions in the activities to claim your credits and receive your certification.
Professor, Psychiatry Institute, Sao Paulo University, Sao Paulo, Brazil